0

    524632

    SHUKRAPHAR

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Shukra Pharmaceuticals Limited Share Price Today

    Investment Returns

    Over 1 Month 5.08% Over 3 Months 3.81% Over 6 Months -24.03% Over 1 Year 42.96%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Shukra Pharmaceuticals Limited fundamentals


    • Market cap (Cr) [-]
    • P/E Ratio (TTM) [-]
    • Beta [-]
    • Book Value / share [-]
    • Return on equity [-]%
    • EPS (TTM) [-]
    • Dividend yield [-]%
    • Net profit/quarter (Cr) [-]
    info icon alternate text
    • Market cap (Cr) 1,323.70
    • P/E Ratio (TTM) 60.36
    • Beta 0.64
    • Book Value / share 2.05
    • Return on equity 15.90%
    • EPS (TTM) 0.50
    • Dividend yield [-]%
    • Net profit/quarter (Cr) -1.73
    info icon alternate text

    Shukra Pharmaceuticals Limited Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 6.30
    Operating Expense 6.88
    Net Profit -1.73
    Net Profit Margin (%) -27.46
    Earnings Per Share (EPS) -0.04
    EBITDA 1.64
    Effective Tax Rate (%) 564.86
    Particulars DEC 2025 (Values in Cr)
    Revenue 39.13
    Operating Expense 13.12
    Net Profit 20.36
    Net Profit Margin (%) 52.03
    Earnings Per Share (EPS) 0.47
    EBITDA 27.95
    Effective Tax Rate (%) 24.11
    Particulars SEP 2025 (Values in Cr)
    Revenue 5.88
    Operating Expense 7.40
    Net Profit 2.38
    Net Profit Margin (%) 40.47
    Earnings Per Share (EPS) 0.05
    EBITDA 1.30
    Effective Tax Rate (%) -1090.00
    Particulars JUN 2025 (Values in Cr)
    Revenue 5.39
    Operating Expense 5.13
    Net Profit 1.03
    Net Profit Margin (%) 19.10
    Earnings Per Share (EPS) 0.02
    EBITDA 2.43
    Effective Tax Rate (%) 24.81
    Particulars MAR 2025 (Values in Cr)
    Revenue 13.27
    Operating Expense 7.16
    Net Profit 5.39
    Net Profit Margin (%) 40.61
    Earnings Per Share (EPS) 0.12
    EBITDA 8.78
    Effective Tax Rate (%) 28.79
    Particulars MAR 2026 (Values in Cr)
    Revenue 56.71
    Operating Expense 32.52
    Net Profit 22.05
    Net Profit Margin (%) 38.88
    Earnings Per Share (EPS) 0.50
    EBITDA 33.30
    Effective Tax Rate (%) 23.35
    Particulars MAR 2025 (Values in Cr)
    Revenue 32.59
    Operating Expense 23.45
    Net Profit 9.58
    Net Profit Margin (%) 29.39
    Earnings Per Share (EPS) 0.22
    EBITDA 16.93
    Effective Tax Rate (%) 28.18
    Particulars MAR 2024 (Values in Cr)
    Revenue 74.57
    Operating Expense 57.51
    Net Profit 18.54
    Net Profit Margin (%) 24.86
    Earnings Per Share (EPS) 16.93
    EBITDA 22.22
    Effective Tax Rate (%) 6.79
    Particulars MAR 2023 (Values in Cr)
    Revenue 58.83
    Operating Expense 55.59
    Net Profit 4.41
    Net Profit Margin (%) 7.49
    Earnings Per Share (EPS) 11.23
    EBITDA 6.56
    Effective Tax Rate (%) 0.90
    Particulars MAR 2022 (Values in Cr)
    Revenue 20.49
    Operating Expense 19.55
    Net Profit 0.75
    Net Profit Margin (%) 3.66
    Earnings Per Share (EPS) 4.79
    EBITDA 2.96
    Effective Tax Rate (%) 26.47
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 1.44
    ROE % 15.90
    ROCE % 21.76
    Total Debt to Total Equity 0.06
    EBITDA Margin 51.95
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 52.65
    ROE % 44.71
    ROCE % 44.16
    Total Debt to Total Equity 0.10
    EBITDA Margin 29.80
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 64.63
    ROE % 21.18
    ROCE % 18.84
    Total Debt to Total Equity 0.20
    EBITDA Margin 11.15
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 104.43
    ROE % 4.69
    ROCE % 5.81
    Total Debt to Total Equity 0.41
    EBITDA Margin 14.49
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 99.63
    ROE % 0.90
    ROCE % 1.35
    Total Debt to Total Equity 0.57
    EBITDA Margin 16.07
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 12.11
    Total Assets 86.76
    Total Liabilities 86.76
    Total Equity 62.83
    Share Outstanding 43
    Price to Book Ratio 15.17
    Return on Assets (%) 11.03
    Return on Capital (%) 14.29
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 9.98
    Total Assets 77.83
    Total Liabilities 77.83
    Total Equity 57.63
    Share Outstanding 1
    Price to Book Ratio 6.20
    Return on Assets (%) 23.81
    Return on Capital (%) 30.49
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 3.97
    Total Assets 74.96
    Total Liabilities 74.96
    Total Equity 25.29
    Share Outstanding 0
    Price to Book Ratio 0.73
    Return on Assets (%) 5.87
    Return on Capital (%) 14.51
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 0.28
    Total Assets 35.11
    Total Liabilities 35.11
    Total Equity 16.35
    Share Outstanding 0
    Price to Book Ratio 0.58
    Return on Assets (%) 2.13
    Return on Capital (%) 3.81
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 0.50
    Total Assets 35.60
    Total Liabilities 35.60
    Total Equity 15.59
    Share Outstanding 0
    Price to Book Ratio 0.45
    Return on Assets (%) 0.52
    Return on Capital (%) 0.74
    Particulars MAR 2025 (Values in Cr)
    Net Income 13.33
    Cash from Operations 11.67
    Cash from Investing -1.26
    Cash from Financing -4.51
    Net change in Cash 2.13
    Free Cash Flow 14.42
    Particulars MAR 2024 (Values in Cr)
    Net Income 19.88
    Cash from Operations -4.57
    Cash from Investing -1.20
    Cash from Financing 12.40
    Net change in Cash 6.00
    Free Cash Flow -2.81
    Particulars MAR 2023 (Values in Cr)
    Net Income 4.44
    Cash from Operations 3.41
    Cash from Investing -4.42
    Cash from Financing 4.94
    Net change in Cash 3.68
    Free Cash Flow 7.91
    Particulars MAR 2022 (Values in Cr)
    Net Income 1.01
    Cash from Operations 8.42
    Cash from Investing -1.52
    Cash from Financing -6.67
    Net change in Cash -0.21
    Free Cash Flow 9.97
    Particulars MAR 2021 (Values in Cr)
    Net Income 0.09
    Cash from Operations 0.53
    Cash from Investing -1.89
    Cash from Financing 1.73
    Net change in Cash 0.37
    Free Cash Flow 2.32
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 34.87 14.47 1.68 267.22 23.12 38.85
    BLISS GVS PHARMA LTD. 467.40 37.63 4.16 4965.84 118.35 552.90
    CIPLA LTD 1472.95 33.25 3.45 118991.58 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 501.25 23.44 3.62 1475.23 256.40 507.20
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 34.87 24.38 4.49 267.22 23.12 38.85
    AMRUTAJAN HEALTH LTD 515.00 23.08 4.02 1488.90 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8103.65 105.90 23.21 20259.13 7630.00 9850.00
    BLISS GVS PHARMA LTD. 467.40 50.58 4.29 4965.84 118.35 552.90

    Shukra Pharmaceuticals Limited shareholding pattern

    Holding
    48.92%
    50.95%
    0.11%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    Shukra Pharmaceuticals Limited Technicals Summary

    30.23 0.16 redarrow
    red-green-graph indicator
    16 Bearish
    0 Bullish
    • 5 Days 30.80
    • 26 Days 31.70
    • 10 Days 31.40
    • 50 Days 31.90
    • 12 Days 31.50
    • 100 Days 33.10
    • 20 Days 31.70
    • 200 Days 33.30
    30.69 PIVOT
    First Support 29.39 First Resistance 31.49 Second Support 28.59 Second Resistance 32.79 Third Support 27.29 Third Resistance 33.59
    RSI 41.42 ADX 16.25 MACD -0.20 Williams % R -95.17 Commodity Channel Index (CCI) -125.15
    Date 2026-07-31 Week 115452.00 Same Day 179043.00 Month 160612.00
    1 Year 0.65 3 Year 0.25
    Over 1 Month
    5.08% down
    Over 1 Year
    42.96% down
    Over 3 Months
    3.81% down
    Over 3 Years
    110.62% down
    Over 6 Months
    -24.03% down
    Over 5 Years
    149.84% down

    Shukra Pharmaceuticals Limited Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    18 Sep 2025 0.01 Final 18 Sep 2025 Equity shares
    23 Sep 2024 1.0 Final 24 Sep 2024 Equity shares
    15 Sep 2023 0.5 Final 16 Sep 2023 Equity shares
    22 Sep 2022 0.5 Final 22 Sep 2022 Equity shares
    19 Sep 2019 0.5 Final 21 Sep 2019 Equity shares
    31 Aug 2018 0.5 Final 04 Sep 2018 Equity shares
    01 Sep 2017 0.5 Final 05 Sep 2017 Equity shares
    Ex-Date Ex-Bonus Ratio
    20 Apr 2024 19 Apr 2024 3:1
    Ex-Date Old FV NEW FV Record Date
    21 Mar 2025 10.0 1.0 21 Mar 2025

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Shukra Pharmaceuticals Ltd?

    Answer Field

    Shukra Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 30.23 as on Aug 03 2026 03:30 PM.

    What is the Market Cap of Shukra Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Shukra Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 1,323.70 as on Aug 03 2026 03:30 PM.

    What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Shukra Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 65.26 and ₹ 17.06.

    What is 1 year return for Shukra Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been 42.96%.

    What is the P/E Ratio of Shukra Pharmaceuticals Ltd Share?

    Answer Field

    As on Aug 03 2026 03:30 PM the price-to-earnings (PE) ratio for Shukra Pharmaceuticals Ltd share is 60.36.

    What is the PB ratio of Shukra Pharmaceuticals Ltd Share?

    Answer Field

    As on Aug 03 2026 03:30 PM, the price-to-book (PB) ratio for Shukra Pharmaceuticals Ltd share is 2.05.

    How to Buy Shukra Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Shukra Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Shukra Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Shukra Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Shukra Pharmaceuticals Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |